Compare BJ & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BJ | RDY |
|---|---|---|
| Founded | 1984 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 11.8B |
| IPO Year | 2018 | 2001 |
| Metric | BJ | RDY |
|---|---|---|
| Price | $92.88 | $12.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | ★ $108.36 | $16.90 |
| AVG Volume (30 Days) | 1.9M | ★ 3.0M |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | ★ 9.50 | N/A |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $21,457,274,000.00 | N/A |
| Revenue This Year | $8.86 | $7.72 |
| Revenue Next Year | $6.50 | $3.50 |
| P/E Ratio | $84.77 | ★ $18.67 |
| Revenue Growth | ★ 4.66 | N/A |
| 52 Week Low | $83.21 | $12.19 |
| 52 Week High | $110.92 | $15.67 |
| Indicator | BJ | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 60.75 | 34.33 |
| Support Level | $88.72 | $12.19 |
| Resistance Level | $95.06 | $13.96 |
| Average True Range (ATR) | 2.54 | 0.37 |
| MACD | 0.78 | -0.23 |
| Stochastic Oscillator | 76.51 | 0.20 |
BJ's Wholesale Club, founded in 1984, operates a membership-based warehouse club model primarily along the US East Coast, with roughly 250 clubs and a growing domestic presence across 21 states. In fiscal 2024, the company generated over $20 billion in revenue. BJ's offers a value-oriented assortment skewed toward grocery, perishables, and consumables (71% of sales), general merchandise (11%), and gasoline (18%). Its business model is supported by recurring membership fee income and private-label brands such as Wellsley Farms and Berkley Jensen.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.